Access Pharmaceuticals has provided an update on its clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.
Reportedly, Access and its partners are finalising development plans and protocols for clinical trials, strategically designed to examine ProLindac in combination with gemcitabine and/or taxol in hepatocellular carcinoma, pancreatic cancer and recurrent ovarian cancer.
Jeffrey Davis, president and CEO at Access, said: “Access is extremely pleased with the clinical progress to date, and look forward to initiation of clinical trials looking at ProLindac in combination with commonly used chemotherapies.
“Our partners in the Far East hosted Access together with key opinion leaders in oncology indications to discuss various potential protocol options, and hope to start enrolling patients in up to three combination trials by the end of the year, depending upon regulatory approvals of the trial protocols and certain other matters.”